T. Rowe Price reports 14.5% stake in Immunome

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 16,364,011 shares of Immunome Inc. common stock, representing 14.5% of the class.

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 16,364,011 shares of Immunome Inc. common stock, representing 14.5% of the class. The filing (Amendment No. 1) lists voting and dispositive powers and identifies T. Rowe Price Small-Cap Stock Fund as holding 5,764,704 shares (5.2%). Signature dated 05/15/2026 appears on the amendment; a date of 03/31/2026 is shown near the cover. The filing states the adviser acts on behalf of clients and disclaims beneficial ownership on its own behalf.

Insights

Institutional Ownership Analyst

Large passive stake reported by a major asset manager.

The filing documents that T. Rowe Price Investment Management, Inc. holds 16,364,011 shares, equal to 14.5% of Immunome Inc.'s common stock as reported. The schedule breaks out voting and dispositive powers, showing sole voting power of 16,346,000 and sole dispositive power of 16,364,011.

Holdings include a named fund with 5,764,704 shares (5.2%). Subsequent trading or reallocation by underlying clients could change reported percentages; future amendments will show material shifts.

Securities Compliance Counsel

Amendment clarifies adviser-held positions and issuer disclosure.

The Schedule 13G/A explicitly states the reporting role of the adviser and includes the customary disclaimer that the adviser does not claim beneficial ownership. The form names the issuer and provides CUSIP 45257U108, and it is signed and dated 05/15/2026.

Regulatory readers should note the adviser-filed structure and client attribution language; filings should be monitored for any change to a Schedule 13D or additional amendments.

Key Figures

Beneficial ownership: 16,364,011 shares Percent of class: 14.5% Sole voting power: 16,346,000 shares +2 more

5 metrics

Beneficial ownership 16,364,011 shares reported in Schedule 13G/A

Percent of class 14.5% percentage of common stock reported

Sole voting power 16,346,000 shares voting power reported on the form

Sole dispositive power 16,364,011 shares dispositive power reported on the form

Named fund holding 5,764,704 shares T. Rowe Price Small-Cap Stock Fund (5.2%)

Key Terms

Schedule 13G/A, beneficial ownership, dispositive power, CUSIP

4 terms

Schedule 13G/A regulatory

"Amendment No. 1) IMMUNOME INC COMMON STOCK"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: 16364011"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power regulatory

"Sole power to dispose or to direct the disposition of: 16364011"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

CUSIP market

"CUSIP No.: 45257U108"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in Immunome Inc. (IMNM)?

T. Rowe Price reports beneficial ownership of 16,364,011 shares, equal to 14.5% of Immunome Inc.'s common stock. The Schedule 13G/A shows sole voting power of 16,346,000 and sole dispositive power of 16,364,011.

Does the filing name any specific T. Rowe Price fund holding IMNM shares?

Yes. The filing identifies T. Rowe Price Small-Cap Stock Fund as holding 5,764,704 shares, representing 5.2% of the class. That holding is disclosed as part of the adviser-managed portfolios.

What dates are shown on the Schedule 13G/A for IMNM?

The cover shows 03/31/2026 near the issuer header and the amendment is signed and dated 05/15/2026 by Ellen York, Vice President. These dates appear inside the amendment text and signature block.

Does T. Rowe Price claim beneficial ownership of the reported shares?

No. The filing includes a clear statement that T. Rowe Price Investment Management, Inc. denies beneficial ownership and states it acts as investment adviser on behalf of clients who hold the economic rights to dividends and sale proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:06 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

IMMUNOME INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

45257U108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45257U108

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 16,346,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 16,364,011.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

16,364,011.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

14.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNOME INC
(b)	Address of issuer's principal executive offices: 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 45257U108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 16364011
(b)	Percent of class: 14.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 16346000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 16364011
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. (2) [T. ROWE PRICE SMALL-CAP STOCK FUND ]: T. ROWE PRICE SMALL-CAP STOCK FUND, of which T. Rowe Price Investment Management, Inc. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. Rowe Price Investment Management, Inc. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE SMALL-CAP STOCK FUND has an interest in 5,764,704 of the class reported herein representing 5.2% of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026